Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

127
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
127
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

123
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
123

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Independent prognostic ımpact of perineural ınvasion in breast cancer patients with residual disease after neoadjuvant chemotherapy.

Revista da Associacao Medica Brasileira (1992)·2026
Same author

An integrated host vulnerability score is associated with survival in advanced NSCLC treated with nivolumab: a PET/CT-based real-world study.

BMC pulmonary medicine·2026
Same author

Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer.

Cancer research·2026
Same author

Concordance between multidisciplinary tumor board decisions and AI-based recommendations in endometrial cancer: impact of discordance direction on clinical outcomes.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Ki-67 Dynamics and Biomarker Conversion as Prognostic Factors in Residual Breast Cancer.

Asia-Pacific journal of clinical oncology·2026
Same author

Comparative Real-World Safety Profiles of Fibroblast Growth Factor Receptor Inhibitors: A Pharmacovigilance Study.

Asia-Pacific journal of clinical oncology·2026

相关实验视频

Updated: Jul 26, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

在接受crizotinib治疗的非小细胞肺癌患者中,估计的淋巴膜过率下降.

Yakup Iriagac1, Eyyup Cavdar1, Kubilay Karaboyun1

  • 1Department of Medical Oncology, Faculty of Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey.

Journal of cancer research and therapeutics
|June 14, 2023
PubMed
概括

治疗非小细胞肺癌的克里佐替尼可能会导致功能暂时下降,以估计的膜过率 (eGFR) 来衡量. 在停止服用药物后,这种eGFR的减少是可逆的.

关键词:
克里佐丁尼布 (crizotinib) 是一种可以球膜过率是指球膜的过率肺癌是一种肺癌.

更多相关视频

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
11:31

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Published on: May 20, 2016

10.8K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

相关实验视频

Last Updated: Jul 26, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K
Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
11:31

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Published on: May 20, 2016

10.8K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

科学领域:

  • 在瘤学瘤学.
  • 腎臟病學 (nephrology) 是一種醫學專業.
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 克里佐替尼 (crizotinib) 是一种用于非小细胞肺癌 (NSCLC) 的氨酸激酶抑制剂.
  • 关于crizotinib对功能的影响存在不确定性.
  • 这项研究调查了crizotinib对NSCLC患者功能不良影响.

研究的目的:

  • 为了评估crizotinib对NSCLC患者功能的影响.
  • 为了记录对脏参数的潜在不良影响.
  • 评估任何观察到的功能变化的可逆性.

主要方法:

  • 使用慢性病流行病学协作 (CKD-EPI) 方程计算估计的淋巴球过率 (eGFR).
  • 基于肌素的eGFR值在治疗前和治疗期间每月间隔进行比较.
  • 采用配对样本t测试和卡普兰-梅尔生存分析.

主要成果:

  • 分析了接受crizotinib的26名NSCLC患者.
  • 在crizotinib治疗的第一个月后,观察到EGFR显著降低 (P < 0.001).
  • 在停止治疗后,eGFR的下降是可逆的,与治疗前水平相比没有显著差异 (P = 0.100).

结论:

  • 克里佐替尼治疗与功能可逆性下降有关.
  • 观察到的下降可能是由于脏炎症或伪减少从改变的肌素分泌.
  • 基于非肌素的eGFR计算方法可以在接受crizotinib的患者中提供更准确的功能评估.